Posted 24th April 2017 by Jane Williams
The 4th Microbiome R&D and Business Collaboration Forum: Europe explored microbiota both inside and outside the gut and examined the role of the human microbiome in various diseases with a focus on modulation and biotherapeutic translation.
Duc H. Le, UK Editor-in-Chief of EBioMedicine, summarises some of the presentations that took place on day one.
Posted 5th April 2017 by Jane Williams
For many years, the gut microbiome has been driving the development of novel probiotic treatments. However, as the first scientifically validated products start to hit the market and more data from clinical trials become available (Olle, 2013), interest in other types of microbiomes is increasing.
Posted 22nd March 2017 by Jane Williams
The term ‘probiotic’ comes from the Greek words ‘προ’ and ‘βιοτος’, which mean ‘for life’. In 1953, the ‘probiotic’ term was introduced by Kollath as organic and inorganic supplements necessary to restore health to patients suffering a form of malnutrition resulting from eating too much highly refined food (Hamilton-Miller et al., 2003).
Posted 17th March 2017 by Jane Williams
Edible fungi or mushrooms are widely used as healthy food and nutraceutical products due to their high nutritive and medicinal value. The world production and consumption of edible and medicinal mushrooms has experienced a steady increase over the last few decades (>25-fold increase in 35 years from 1978 – 2012) and is projected to grow at 9.5% annually from 2014 to 2019, tripling the world GDP growth from 2013 – 2018 (2.5 – 3.0%).
Posted 10th March 2017 by Jane Williams
Physical, chemical and biological stresses are the order of the day for cultured fish. The expansion of aquaculture over the last three decades to complement capture fisheries means that farmers are increasing stocking densities and feed input per production unit.
Posted 8th February 2017 by Jane Williams
Dysbiotic characteristics are increasingly attributed to a range of serious, and sometimes fatal, digestive disorders affecting humans. These include inflammatory bowel diseases, chemotherapy-induced mucositis, radiation enteritis, NSAID-enteropathy and colon cancer.
Posted 25th November 2016 by Jane Williams
Artificial digestive systems are increasingly used as a relevant alternative to in vivo studies for ethical, technical, regulatory and cost reasons. For more than 20 years, CIDAM, from the University of Auvergne in France, has been developing platforms such as the artificial digestion associating dissolution apparatus, mastication simulator, gastric and small intestinal models, large intestinal systems and intestinal cells in culture.
Posted 14th October 2016 by Jane Williams
A scientist at DuPont Nutrition and Health, Nicolas Yeung’s research focus is on the effect of probiotics on human health. qPCR has enabled advances in his research, however it also comes with some potential sources of error. We had a chat with Nicolas ahead of the qPCR and Digital PCR Congress, where he will discuss the approaches to tackling these issues.